Mylan Loses Bid To Dismiss Arthritis Drug Suit

Law360, New York (September 10, 2008, 12:00 AM EDT) -- A federal judge on Tuesday refused to dismiss a proposed class action against Mylan Laboratories Inc. that alleges the company's arthritis treatment piroxicam, a generic version of Pfizer Inc.'s Feldene, puts users at increased risk for a disease that causes severe rashes and blisters.

Judge Reginald C. Lindsay of the U.S. District Court for the District of Massachusetts denied Mylan's motion to dismiss the suit "in light of the filing of an amended complaint" on Aug. 25.

The suit, first filed in February, alleges that Mylan's...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.